Posted by Michael Wonder on 17 Jul 2020
Xenleta (lefamulin) receives Health Canada approval for treatment of community acquired pneumonia
16 July 2020 - Nabriva Therapeutics announced today that its partner, Sunovion Pharmaceuticals, has received approval from Health Canada to market oral and intravenous formulations of Xenleta (lefamulin) for the treatment of community-acquired pneumonia in adults.
Nabriva entered into a license and commercialisation agreement in March 2019 with Sunovion Pharmaceuticals for Xenleta in Canada.
